Objective: To evaluate obstetric outcomes with oocyte vitrification after ovarian stimulation (OS) and in vitro maturation (IVM) of immature oocytes.

Design: A prospective trial from October 2003 to April 2007.

Setting: University-based medical center.

Patient(s): OS group: 38 patients undergoing intrauterine insemination who overresponded to OS. IVM group: 20 patients who had previous unsuccessful intrauterine insemination.

Intervention(s): Mature oocyte retrieval following OS. Immature oocyte retrieval and IVM. Oocyte vitrification, thawing, insemination, and transfer of the resulting embryos.

Main Outcome Measure(s): Live-birth rates and obstetric outcomes.

Result(s): The OS group was superior to the IVM group in terms of oocyte survival (81.4 +/- 22.6% vs. 67.5 +/- 26.1%), fertilization rate (75.6 +/- 22.5% vs. 64.2 +/- 19.9%), and cumulative embryo score (38.4 +/- 22.3 vs. 20.0 +/- 13.8). However, the differences in the implantation rate per embryo (19.1 +/- 25.8% vs. 9.6 +/- 24.1%), clinical pregnancy rate per cycle started (44.7%, vs. 20.0%), and live-birth rate per cycle started (39.5% vs. 20.0%) were not statistically significant. Twenty healthy babies were born in the OS group and four in the IVM group.

Conclusion(s): Pregnancies achieved with vitrification of oocytes after OS and IVM treatments do not appear to be associated with adverse pregnancy outcomes. Vitrification of IVM oocytes represents a novel option for fertility preservation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fertnstert.2008.04.014DOI Listing

Publication Analysis

Top Keywords

obstetric outcomes
8
outcomes vitrification
8
oocyte vitrification
8
group patients
8
ivm group
8
oocyte retrieval
8
+/-
8
rate cycle
8
cycle started
8
ivm
7

Similar Publications

Background: As induction of labor increases in the United States, safe, effective outpatient cervical ripening has been explored as a method to decrease the inpatient time burden. The most effective method of outpatient mechanical cervical ripening remains unclear.

Objective: To evaluate if Dilapan-S is non-inferior to cervical balloon for outpatient cervical ripening (CR) based on change in Bishop score.

View Article and Find Full Text PDF

Nitroglycerine for retained placenta: a meta-analysis of randomized controlled trials.

Am J Obstet Gynecol MFM

January 2025

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA. Electronic address:

Objective: To evaluate the effect of nitroglycerine on placenta delivery after retained placenta DESIGN: Systematic review with meta-analysis DATA SOURCES: MEDLINE, PROSPERO, Scopus, ClinicalTrials.gov, EMBASE, Sciencedirect, the Cochrane Library, Scielo were searched from their inception until February 2024.

Eligibility Criteria For Selecting Studies: We included all randomized clinical trials comparing use of nitroglycerine (i.

View Article and Find Full Text PDF

Research Question: Does endometrial preparation using a natural cycle lead to higher live birth rates (LBR) in single euploid frozen embryo transfers (FET) compared with programmed cycles, for women who are normal weight, overweight and obese.

Design: Retrospective study of 845 single euploid FETs from 688 couples. Patients were stratified by body mass index (BMI) into normal weight, overweight and obesity class I/II categories.

View Article and Find Full Text PDF

Introduction: Despite research supporting menopause hormonal therapy for menopausal women, its use continues to decline in most European countries and the United States. Experts highlighted the need for global assessment tools to assist clinicians in evaluating treatment for symptomatic menopausal women, which led to the development of the Menopause Treatment Tool, with separate versions for women and healthcare professionals. Both versions of the tool focus on menopausal symptoms, risk levels and suggested actions; the women's tool is administered prior to the consultation, while the clinician tool is administered by the clinician during the clinical consultation.

View Article and Find Full Text PDF

Antagonisation of Prokineticin Receptor-2 Attenuates Preeclampsia Symptoms.

J Cell Mol Med

January 2025

Interdisciplinary Research Institute of Grenoble, IRIG-Biosanté, University Grenoble Alpes, INSERM, CEA, UMR 1292, Grenoble, France.

Preeclampsia (PE) is the most threatening pathology of human pregnancy. Placenta from PE patients releases harmful factors that contribute to the exacerbation of the disease. Among these factors is the prokineticin1 (PROK1) and its receptor, PROKR2 that we identified as a mediators of PE.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!